At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 779 enrolled
Drug / intervention
bempedoic acid +1 moredrug
Likely dose
bempedoic acid 180 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy
In Brief
A Phase 3 clinical trial evaluating bempedoic acid and placebo for Hypercholesterolemia and Atherosclerotic Cardiovascular Disease. Completed, enrolled 779 participants across 2 sites.
Detailed Summary
The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedDec 2016
Primary CompletionAug 2018
TodayJul 2026
First PostedDec 13, 2016
Enrollment StartNov 18, 2016
Primary CompletionAug 22, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.6 years ago
Interventions
bempedoic aciddrug
bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
placebodrug
Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)